34 results on '"van Kooten, Job P."'
Search Results
2. Treatment and Survival Outcomes for Patients with Colorectal Peritoneal Metastases Deemed Ineligible for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Results of a Retrospective Study
3. Impact of centralization of care for malignant peritoneal mesothelioma: A historical cohort study from the Dutch mesothelioma expert centers
4. Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Versus Metachronous Onset of Peritoneal Metastases of Colorectal Carcinoma
5. The Impact of Low Skeletal Muscle Mass on Short- and Long-Term Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
6. ASO Visual Abstract: Treatment and Survival Outcomes of Patients with Colorectal Peritoneal Metastases Deemed Ineligible for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Results of a Retrospective Study
7. Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice
8. ASO Visual Abstract: Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Versus Metachronous Onset of Peritoneal Metastases of Colorectal Carcinoma
9. Predictive Ability of C-Reactive Protein in Detecting Short-Term Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Cross-Sectional Study
10. ASO Visual Abstract: The Impact of Low Skeletal Muscle Mass on Short- and Long-Term Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
11. Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study
12. Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial
13. Pressurized aerosol versus catheter-based intraperitoneal chemotherapy in patients with extensive colorectal peritoneal metastases – comparing results of two early phase trials.
14. Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases
15. Intraperitoneal irinotecan combined with systemic chemotherapy for extensive peritoneal carcinomatosis of colorectal origin: The phase I and phase II INTERACT trials
16. Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma:a phase II clinical trial
17. ASO Visual Abstract:Treatment and Survival Outcomes of Patients with Colorectal Peritoneal Metastases Deemed Ineligible for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Results of a Retrospective Study
18. Impact of centralization of care for malignant peritoneal mesothelioma:A historical cohort study from the Dutch mesothelioma expert centers
19. ASO Visual Abstract
20. Treatment and Survival Outcomes for Patients with Colorectal Peritoneal Metastases Deemed Ineligible for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Results of a Retrospective Study
21. Impact of centralization of care for malignant peritoneal mesothelioma: A historical cohort study from the Dutch mesothelioma expert centers
22. Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO
23. ASO Visual Abstract
24. Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma:a population-based study
25. Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma:a phase I/II dose escalation and safety study-INTERACT MESO
26. Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study
27. Nasogastric- vs. percutaneous gastrostomy tube for prophylactic gastric decompression after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
28. Nasogastric- vs. percutaneous gastrostomy tube for prophylactic gastric decompression after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
29. Predictive Ability of C-Reactive Protein in Detecting Short-Term Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Cross-Sectional Study
30. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
31. Mesenchymal Stromal Cell-Derived Factors Promote Tissue Repair in a Small-for-Size Ischemic Liver Model but Do Not Protect against Early Effects of Ischemia and Reperfusion Injury
32. Molecular aberrations and potential actionable mutations in malignant peritoneal mesothelioma: A scoping review.
33. Survival Outcomes after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in patients with Synchronous versus Metachronous onset of Peritoneal Metastases of Colorectal Carcinoma.
34. The impact of Sarcopenia on Short and Long Term Outcomes after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.